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Varicella-zoster vwirus (VZV) persists in human sensory ganglia. One of the hypotheses to explain the
induction or the maintenance ofVZV latency is that it could be promoted by the immune response itself. It is
known that in the case ofviruses which bud off the infected cell membrane, virus-specific antibodies can induce
antigenic modulation, i.e., spatial redistribution of viral antigens and modulation of their synthesis. To
determine whether antigenic modulation occurs during VZV infection in vitro and could possibly be involved
in viral persistence, we have grown infected cells in the presence of anti-VZV antibodies either transiently or
permanently. The distribution of immune complexes and viral proteins was then analyzed. In transient
immunomodulation experiments, the distribution of one or more viral antigens was modified not only in the
cytoplasmic membranes but also in the cytoplasm and nucleoplasm of infected cells. When infected cells were
kept permanently in the presence of antibodies, the same pattern of redistribution of immune complexes was
observed and the localization ofinternal viral glycoproteins was significantly modified. However, antibodies did
not prevent the ytic effect of infection; they altered neither the infectious virus yield nor the Western
immunoblot pattern of viral proteins, suggesting that immunomodulation is not the primary effector of viral
persistence.
Varicella-zoster virus (VZV) is a human herpesvirus
which causes a primary infection in childhood, becomes
latent in dorsal root ganglia, and can be reactivated many
years later to produce shingles in adults (10). Investigation of
mechanisms by which viruses become persistent and remain
latent in infected cells progresses along two paths: (i)
searches for a viral gene that is directly or indirectly respon-
sible for latency and (ii) identification of host factors that
induce viral latency. In the latter case, the main factor of
interest is the host immune system. It has been shown that
both in vitro and in vivo, persistence of a virus which buds
at the plasma membrane of infected cells can be induced by
the presence of antiviral antibodies at the time of virus
maturation (20-23). Antibody treatment can induce a redis-
tribution of membrane antigens which are assembled in
patches and then in caps, as has been well documented for
enveloped viruses budding at the plasma membrane, such as
measles virus (8, 9, 13, 18), a retrovirus (19), or influenza
virus (24). Studies of measles virus have demonstrated that
the effect of antibodies on the viral replication cycle is not
restricted to a mechanical hindrance of the budding process.
In fact, antibodies modulate through an unknown mecha-
nism the synthesis of the viral glycoproteins expressed on
the cell surface before budding (5-7, 14). Regulation of gene
expression has also been described for a parvovir'us (1) and
a coronavirus (3). The phenomenon of specific regulation of
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gene expression by antibodies was first described for cellular
structural proteins and called immunomodulation by Stack-
pole et al. (25). Such an immunomodulating effect on viral
gene transcription could lead to persistence (17) and could
account, on a mdlecular basis, for the data obtained for the
induction of persistence by antibody pressure.
At first sight, such a phenomenon may seem rather un-
likely for viruses of the family Herpesviridae, since they are
known to mature at the inner nuclear membrane and in
cytoplasmic vesicles. However, viral glycoproteins are ex-
pressed on the plasma membrane during infection. These
proteins do not participate in the assembly of the viral
particle, but they are fully accessible and can thus be targets
for antiviral antibodies. During latency, high anti-VZV anti-
body levels can be detected (2), but their role in the
induction or maintenance of a quiescent state is unknown.
Indeed, in the case of herpes simplex virus infection, it is not
clear whether the binding of immunoglobulins to virus-
induced Fc receptors plays (4) or does not play (11) a role in
the inhibition of virus growth. Even though our laboratory
studies can only mimic the in vivo situation, it is worth
controlling the direct effect of antibodies on the course of
viral infection. We have thus tested the immunomodulation
hypothesis in order to confirm it or to rule it out, at least
under in vitro conditions.
MRC-5 cells (human embryonic lung fibroblasts; Bi-
om6rieux, Marcy I'Etoile, France) were maintained in Ea-
gle's basal medium (GIBCO Laboratories, Grand Island,
N.Y.) supplemented with 10% fetal calf serum, 100 U of
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TABLE 1. Molecular weights and identities of polypeptides
recognized by monoclonal antibodies
Monoclonad Mol wt (1O3) Identityantibody
Biosoft 215-84/101 49 and 39 gpII
VL1 49 and 39 gpII
VL8 70, 63, and 57 gpl
penicillin per ml, 100 mg of streptomycin per ml, and 0.15%
NaHCO3.
The original strain of VZV used in this study was isolated
by sterile aspiration of vesicular lesions of a patient with
chicken pox. Restriction analysis of the purified DNA
showed the typical pattern of VZV Ellen strain. Infection
was propagated by cocultivation of MRC-5 cells with VZV-
infected MRC-5 cells (ratio of 1 infected cell to 3 uninfected
cells).
Human anti-VZV antibodies were prepared by ammonium
sulfate precipitation of a non-convalescent-phase human
plasma with high anti-VZV antibody activity (>12,800 in
enzyme immunoassay) and dialysis at 4° C in phosphate-
buffered saline (PBS). Anti-VZV rabbit hyperimmune serum
was obtained by immunization with VZV purified from
infected MRC-5 cells followed by three steps of absorption
on uninfected cells to decrease reactivity against nonviral
antigens. Monoclonal antibodies were either obtained from
Biosoft (Paris, France) (215-84/101) or produced in our
laboratory (VL1 and VL8). The molecular weights of the
viral polypeptides recognized by these monoclonal antibod-
ies are listed in Table 1. The specificity of each antiserum or
monoclonal antibody was verified by immunohistology or
Western blotting (immunoblotting) analysis on infected and
uninfected cells.
MRC-5 cells infected by cocultivation with VZV-infected
or mock-infected cells were treated with human anti-VZV
antibodies (1/20 in cell culture medium) either transiently (2
h) or permanently (for 72 h) (Fig. 1).
Viral antigens were detected by surface immunolabeling
on cells fixed with 4% (wt/vol) paraformaldehyde in PBS (pH
7.6) (20 min at 20° C). For intracellular labeling, cells were
fixed in acetone for 5 min (-20° C), dried, and stored at
-20° C until use or fixed in paraformaldehyde, permeated
with 95% ethanol (15 min at -20° C), and stored at 4° C. Just
before use, cells were rehydrated in PBS at 20° C for 5 min.
After saturation with skimmed milk (15 g/liter in PBS) for 30
min at 20° C, viral antigens were labeled by incubation either
with rabbit anti-VZV antibody (1:50 in PBS, 60 min at 37° C)
or with a monoclonal antibody or a human plasma with high
anti-VZV antibody activity (1:40 in PBS, 60 min at 37° C).
After four washes with PBS, endogenous peroxidase was
inactivated by a treatment with 0.03% (vol/vol) hydrogen
peroxide in PBS for 15 min. Then goat anti-rabbit immuno-
globulin (Ig), rabbit anti-mouse IgG, or rabbit anti-human
IgG antibody coupled to peroxidase (Dako, Glostrup, Den-
mark) (1:40 in PBS, 60 min at 37° C) was added. The presence
of peroxidase was revealed with diaminobenzidine tetrachlo-
ride (0.5 mg/ml in PBS) and 0.01% (vol/vol) hydrogen
peroxide.
Viral antigens were analyzed by Western blotting (26).
They were produced from infected cells by washing the cells
several times with serum-free culture medium, mechanically
scraping the cells off the plastic substrate in PBS, and
centrifugating the cells for 10 min at 400 x g. The pellets
corresponding to 75 cm2 of cells were then resuspended
either in 0.5 ml of RIPA mixture (12) or in the same volume
of PBS prior to ultrasonication for 1 min. Finally, the
material was centrifuged at 200 x g for 15 min. Antigens
were treated 1:1 (vol/vol) in a denaturing mix (0.125 M
Tris-HCl [pH 6.8], 4% [wtlvol] sodium dodecyl sulfate
[SDS], 20% [vol/vol] glycerol, 10% [vol/vol] ,B-mercaptoeth-
anol, 5% [vol/vol] bromophenol blue) and then heated at
100° C for 90 s. Samples (3.75 ,ug of proteins [16] in each well)
infection wash wash A
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FIG. 1. Schematic representation of transient (A) and permanent (B) immunomodulation
corresponds to duration of antibody treatment. Arrowheads indicate times of sample fixation.
treatment protocols. The thick arrow
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FIG. 2. Detection of antigen-antibody complexes on the surface of VZV-infected cells cultured with anti-VZV human antibodies for 2 h
(transient immunomodulation). The complexes were detected by immunoperoxidase with a rabbit peroxidase-labeled anti-human Ig (Dako)
on cells fixed 0 (A), 1 (B), or 3 (C) h after immunomodulation treatment. Patches (arrows) and a cap (arrowhead) are indicated. Magnification,
x240.
were applied on polyacrylamide gels (4% [wt/vol] in 0.5 M
Tris-HCl [pH 6.8] for the stacking gels; 8% [wt/vol] in 1.5 M
Tris-HCl [pH 8.8] for the separating gels). Electrophoresis
was run at 150 V in 0.025 M Tris (pH 8.3)-0.2 M glycine-
0.1% (wt/vol) SDS. Proteins were transferred onto an Im-
mobilon membrane (Millipore) in a Biolyon dry electroblot-
ter according the manufacturer's instructions (1 h at 24 V).
Transient immunomodulation experiments were per-
formed to verify whether antibodies could bind to viral
antigens on living cells and could thus induce modifications
of viral expression. Human anti-VZV antibodies were added
to the culture medium 24 h after infection, maintained for 2
h, and then removed (Fig. 1A). Mock-infected cells were
cultured and treated in the same way. The fate of antigen-
antibody complexes was monitored. When cultured infected
cells were exposed to antibodies specific of their membrane
constituents, the immune complexes formed either were
internalized (15) or remained on the cell membrane (20).
When cells were fixed at various times after immunomodu-
lation and then incubated with rabbit anti-human IgG anti-
bodies coupled to peroxidase (Dako) (1/40 in PBS, 60 min at
37° C), immune complexes were never detected on the sur-
face of uninfected cells, and a typical patching and capping
effect was observed on infected cells. The presence of
membranous antigen-antibody complexes formed during the
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FIG. 3. Immunoperoxidase labeling of viral antigen with a mono-
clonal antibody (Biosoft 215-84/101) on VZV-infected cells. Cells
were cultured without (A) or with (B and C) anti-VZV human
antibodies for 2 h, rinsed, and then fixed with acetone immediately
(B) or after 1 h (C). Magnification, x440.
beled anti-human Ig antibody. Such complexes were homo-
geneously distributed on the cell surface immediately after
antibody treatment (Fig. 2A). If cells were allowed to
recover after treatment, immune complexes formed patches
randomly scattered on the surface (Fig. 2B) and then gath-
ered in a cap (Fig. 2C). Endocytosis followed; no labeling
was detected after paraformaldehyde fixation, whereas cy-
toplasmic labeling was observed after acetone fixation, after
which there was almost complete clearance of complexes
from the cells.
The effect of antibody treatment was significant when free
antigenic sites were observed by immunoperoxidase label-
ing. The most striking observation was the profound modi-
fication of the localization of viral epitopes recognized by an
anti-gpII monoclonal antibody after the transient treatment.
In untreated cells, an epitope with a nuclear and cytoplasmic
distribution was observed (Fig. 3A). This distribution be-
came exclusively cytoplasmic when cells were cultured for 2
h in the presence of anti-VZV antibodies (Fig. 3B). When
antibodies were washed away, it took only 60 min for the
epitope localization to become nuclear again (Fig. 3C). This
modification of viral epitope localization was confirmed with
an anti-gpI monoclonal antibody.
However, viral protein expression was unchanged quali-
tatively and perhaps only slightly delayed by transient
immunomodulation; the anti-gpII monoclonal antibodies re-
vealed two major bands (49 and 39 kDa) in Western blot
analysis of VZV-infected MRC-5 cells, even in untreated
cells and cells transiently treated with human anti-VZV
antibodies (Fig. 4). In the same way, no modification of the
expression of viral proteins recognized by rabbit anti-VZV
hyperimmune serum has been detected.
These transient immunomodulation experiments indicated
that under the conditions described, antibodies reacted with
luntreated 1 49K 39KI--antibody-treatedlI
S~ ~ ~~~1
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FIG. 4. Electrophoretic profile of viral antigens revealed after
Western blotting. Cells were cultured without or with anti-VZV
human antibodies during 2 h and recovered 48 h after infection. Viral
polypeptides were detected with an anti-gpII monoclonal antibody.
C
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FIG. 5. Electrophoretic profile of viral antigens revealed after Western blotting. Cells were cultured without or with anti-VZV human
antibodies during 48 h and then recovered. Viral polypeptides were detected with an anti-gpII monoclonal antibody (A) or a rabbit anti-VZV
hyperimmune serum (B).
viral antigens on infected cells in such a manner that they
could induce significant modifications in these cells. Perma-
nent immunomodulation experiments could then be under-
taken. Infected and mock-infected cells were cultured in the
presence of human anti-VZV antibodies for various times
and then fixed (Fig. 1B). The effects of immunomodulation
were studied by searching for immune complexes on the cell
surface, modifications of localization and expression of viral
polypeptides, and production of infectious virus. The same
pattern of redistribution of immune complexes on the cell
surface was observed, and modifications of the localization
of internal viral glycoproteins occurred as in transient treat-
ment. Expression of viral polypeptides after 48 h of culture
in the presence of anti-VZV antibodies was qualitatively
unmodified, as indicated by Western blotting analysis with
TABLE 2. Infectivity after permanent immunomodulation
Antibody Duration (h) of Infectivity





an anti-gpII monoclonal antibody (Fig. SA) or with rabbit
anti-VZV antibodies (Fig. SB). Any quantitative differences
that appeared seemed to reflect variations in the evolution of
infection in cell cultures.
Treated and untreated cells were scraped, pelleted, and
ultrasonicated. Supernatants were inoculated on uninfected
MRC-5 cells, and foci were counted after 4 days. Infectious
titers remained unchanged and evolved similarly whether
cells had been treated or not (Table 2).
Our data indicate that antibody treatment of infected
MRC-5 cells, although playing a dramatic role in the intrac-
ellular localization of viral glycoproteins, has, surprisingly,
no apparent effect on viral maturation and assembly. Since
polypeptides present at the cell surface and capable of
interacting with antibodies during immunomodulation treat-
ment are glycoproteins, we used antiglycoprotein antibodies
for characterization of the immunomodulation effects. How-
ever, it remains possible that a change in expression or
localization of nonglycosylated polypeptides occurs in re-
sponse to antibody pressure, but in this case, it does not
seem to alter production of infectious particules. Such an
immunomodulation treatment is thus obviously unable to
induce persistent VZV infection in vitro. The correlation
between the permanent presence of anti-VZV antibodies in
body fluids during the latent phase of infection and the
VOL. 66, 1992
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induction of a quiescent state is thus weakened by our
observations. However, our findings do not exclude a role
for humoral immunity in maintaining VZV latency once it
has been induced.
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